SLC5A2 and heart failure: Our results expand on similar findings in non-HF patients with type 2 diabetes treated with SGLT2 inhibitors14–16 and are consistent with changes in markers of systemic iron metabolism after 12 months’ exposure to dapagliflozin in a recent analysis from the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study20.